



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
Group Art Unit 1624

In re

Patent Application of

David Edwin Thurston, et al.

Application No. 10/602,521

Confirmation No.: 2183

Filed: June 24, 2003

Examiner: \_\_\_\_\_

“COLLECTION OF COMPOUNDS”

I, Julie Mallder, hereby certify that this correspondence is being deposited with the US Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date of my signature.

Julie Mallder  
Signature

November 10, 2003  
Date of Signature

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 CFR §1.97(b)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


The Examiner's attention is directed to the references which are listed on the attached Form PTO/SB/08A and/or PTO/SB/08B, copies of which are not being provided herewith because, pursuant to 37 C.F.R. §1.98(d), copies were previously submitted to, or cited by, the office in U.S. Serial No. 09/763,768, filed February 26, 2001, which is being relied upon for an earlier filing date under 35 U.S.C. §120.

This information disclosure statement is being filed before the mailing of the first office action on the merits.

Citation of these references is respectfully requested.

No concession is made that these documents are prior art, and Applicant expressly reserves the right to antedate the documents as may be appropriate.

Respectfully submitted,


A handwritten signature in black ink, reading "Charlene L. Yager". The signature is written in a cursive, flowing style with a large, prominent "C" and "Y".

Charlene L. Yager  
Reg. No. 48,887

File No. 065435-9027

Michael Best & Friedrich LLP  
One South Pinckney Street  
P. O. Box 1806  
Madison, WI 53701-1806  
(608) 257-3501

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		<b>Complete if Known</b>	
		Application Number	10/602,521
		Filing Date	June 24, 2003
		First Name Inventor	David Edwin Thurston
		Group Art Unit	1624
Sheet 1 of 1		Examiner Name	
		Attorney Docket Number	065435-9027

U.S. PATENT DOCUMENTS				
Examiner Initials		U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
		4,239,683	Yoshio Arakawa	12/16/1980
		3,524,849	Batcho <i>et al.</i>	8/18/1970
		3,523,941	Leimgruber <i>et al.</i>	8/11/1970
		5,545,568	Ellman	8/13/1996
		4,309,437	Ueda <i>et al.</i>	1/1982


FOREIGN PATENT DOCUMENTS						
Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
	JP	JP 58 180 487	Kyowa Hakko Kogyo Co. Ltd.	10/21/1983		
	JP	JP 57 131 791	Fujisawa Yakuhin Kogyo KK	8/14/1982		
	FR	FR 2 586 683	Centre National de la Recherche Scientifique	3/6/1987		
	GB	GB 1 299 198		12/6/1972		
	WO	WO 92/19620	Centre National de la Recherche Scientifique	11/12/1992		
	WO	WO 97/01560	Pharmacoepia, Inc.	1/16/1997		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.




<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/602,521
				Filing Date	June 24, 2003
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	
Sheet	1	of	8	Attorney Docket Number	065435-9027

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		Althuis, T.H. and Hess, H.J, <i>J. Medicinal Chem.</i> , 20(1), 146-149 (1977).
		Arima <i>et al.</i> , <i>J. Antibiotics</i> , 25, 437-444 (1972).
		Aristoff, <i>J. Org. Chem.</i> , 57, 6234-6239 (1992).
		Baraldi, P. G. <i>et al.</i> , "Design, synthesis and biological activity of a pyrrolo [2,1-c] [1,4]benzodiazepine (PBD)-distamycin hybrid", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , vol. 8, no. 21, 3019-3024 (1998).
		Bi, Y., <i>et al.</i> , <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , vol. 6, no. 19, 2299-2300 (1996).
		Boger <i>et al.</i> , <i>Chem. Rev.</i> , 97, 787-828 (1997).
		Bose <i>et al.</i> , <i>Tetrahedron</i> , 48, 751-758 (1992)
		Bose, D.S., <i>et al.</i> , <i>J. Am. Chem. Soc.</i> 1992, 114, 4939-4941.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.


<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/602,521
				Filing Date	June 24, 2003
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	
Sheet	2	of	8	Attorney Docket Number	065435-9027

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		Brown, S C <i>et al.</i> , <i>Science</i> , 265, 777 (1994).
		Burgess, K. <i>et al.</i> , "Solid Phase Synthesis of Oligoureas", <i>Journal of the American Chemical Society</i> , 119: 1556-64 (1997).
		Burgess, K. <i>et al.</i> , "Solid Phase Synthesis of Unnatural Biopolymers Containing Repeating Urea Units" <i>Angew Chem. Int. Ed. Engl.</i> , 34, No. 8:907 (1995).
		Cava <i>et al.</i> , Drost, K. J., Cava, M. P., <i>J. Org. Chem.</i> , 56, 2240-2244 (1991).
		Chemical Abstract No. 171573p, O'Neil, "The synthesis of Functionalized Pyrrolo-[2,1-c][1,4]-Benzodiazepines", <i>Chemical Abstracts</i> , vol. 126, no. 13, 618 (1997) and entire article.
		Chemical Abstract No. 239940r, Farmer, "DNA binding properties of a new class of linked anthramycin analogs", <i>Chemical Abstracts</i> , vol. 114, no. 25, 25 (1991) and entire article.
		Chemical Abstract No. 4427a, Umezawa, "Mazethramycins" <i>Chemical Abstracts</i> , vol. 90, no. 1, 428 (1979).
		Chemical Abstract No. 72145x, Fujisawa, "Benzodiazepine derivatives", <i>Chemical Abstracts</i> , vol. 98, no. 9, 638 (1983).
		Chemical Abstracts No. 139983k, Fujisawa, <i>Chemical Abstracts</i> , vol. 99, no. 17, 603 (1983).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/602,521
				Filing Date	June 24, 2003
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	
Sheet	3	of	8	Attorney Docket Number	065435-9027


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		Chemical Abstracts, Yingzhi, Bi. <i>et al.</i> , "Building blocks for peptide and carbamate libraries", <i>Chemical Abstracts</i> , vol. 125, no. 23, 1013 (1996).
		Cho, C Y <i>et al.</i> , "An Unnatural Biopolymer", <i>Science</i> , 261: 1303-5 (1993).
		Courtney, S. M. <i>et al.</i> , "A new convenient procedure for the synthesis of pyrrolo[2,1-c][1,4]benzodiazepines", <i>Tetrahedron Letters</i> , vol. 34, no. 33, 5327-28 (1993).
		Damayanthi, Y., <i>et al.</i> , "Design and synthesis of novel pyrrolo{2,1-c}[1,4] benzodiazepine-Lexitropsin Conjugates," <i>J. Org. Chem.</i> , 64, 290-292 (1999).
		Edman, P. and Begg, G., <i>Eur. J. Biochem.</i> , 1, 80 (1967).
		Figliozi, GMR <i>et al.</i> , "Synthesis of N-substituted Glycine Peptoid Libraries", <i>Methods in Enzymology</i> , 267, 437-47 (1996).
		Foloppe, M.P., <i>et al.</i> , "DNA-binding properties of pyrrolo[2,1-c][1,4]benzodiazepine N10-C11 amidines" <i>Eur. J. Med. Chem.</i> , 31, 407-410 (1996).
		Fukuyama, T. <i>et al.</i> , "Total synthesis of (+)-porothramycin B", <i>Tetrahedron Letters</i> , vol. 34, no. 16, 2577-2580 (1993).
		Furka, A. <i>et al.</i> , <i>International Journal of Peptide and Protein Research</i> , 37, 487-493 (1991).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.




<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/602,521
				Filing Date	June 24, 2003
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	
Sheet	4	of	8	Attorney Docket Number	065435-9027

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		Gregson, S. J. <i>et al.</i> , "Synthesis of a novel C2/C2' -exo unsaturated pyrrolbenzodiazepine cross-linking agent with remarkable DNA binding affinity and cytotoxicity", <i>Chemical Communications</i> , 797-798 (1999).
		Guiotto A. <i>et al.</i> , "Synthesis of novel C7-aryl substituted pyrrolo [2,1-c] [1,4]benzodiazepines (PBDs) via Pro-N10-troc protection and suzuki coupling", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , vol. 8, no. 21, 3017-3018 (1998).
		Hara <i>et al.</i> , <i>J. Antibiotics</i> , 41, 702,704 (1988).
		Hara <i>et al.</i> , <i>J. Antibiotics</i> , 41, 1366-1373 (1988).
		Hochlowski <i>et al.</i> , <i>J. Antibiotics</i> , 40, 145-148 (1987).
		Hurley and Needham-VanDevanter, <i>Acc. Chem. Res.</i> , 19, 230-237 (1986).
		Itoh <i>et al.</i> , <i>J. Antibiotics</i> , 41, 1281-1284 (1988).
		Jenkins, T.C., <i>et al.</i> , <i>J. Med. Chem.</i> 1994, 37, 4529-4537
		Kohn, <i>Antibiotics III</i> , Springer-Verlag, NY, 3-11 (1975).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/602,521
				Filing Date	June 24, 2003
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	
Sheet	5	of	8	Attorney Docket Number	065435-9027


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		Konishi <i>et al.</i> , <i>J. Antibiotics</i> , 37, 200-206 (1984).
		Kunimoto <i>et al.</i> , <i>J. Antibiotics</i> , 33, 665-667 (1980).
		Langley and Thurston, <i>J. Org. Chem.</i> , 52, 91-97 (1987).
		Leber <i>et al.</i> , <i>J. Am. Chem. Soc.</i> , 110, 2992-2993 (1988).
		Leimgruber <i>et al.</i> , <i>J. Am. Chem. Soc.</i> , 87, 5791-5793 (1965).
		Leimgruber <i>et al.</i> , <i>Am. Chem. Soc.</i> , 87, 5793-5795 (1965).
		Lescrinier, <i>et al.</i> , <i>Chem. Eur. J.</i> , 425-433 (1998).
		Lown <i>et al.</i> , <i>Biochem. Pharmacol.</i> (1979), 28 (13), 2017-26; Abstract
		M Egholm <i>et al.</i> , <i>JACS</i> , 114, 1895 (1992).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.


<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/602,521
				Filing Date	June 24, 2003
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	
Sheet 6 of 8	Attorney Docket Number	065435-9027			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		M Egholm <i>et al.</i> , <i>Nature</i> , 365, 566 (1993).
		Monks, A. <i>et al.</i> , <i>Journal of National Cancer Institute</i> , 83, 757 (1991).
		Moran, E J, <i>et al.</i> , "Novel Biopolymers for Drug Discovery. Biopolymers", <i>Peptide Science, John Wiley and Sons</i> , 37: 213-19 (1995)
		Nagasaka, T. <i>et al.</i> , "Stereoselective synthesis of Tilivalline", <i>Tetrahedron Letters</i> , vol. 30, no. 14, 1871-72 (1989).
		Nagasaka, T. <i>et al.</i> , "Stereoselective synthesis of tilivalline", <i>Journal of Organic Chemistry</i> , vol. 36, no. 20, 6797-6801 (1998).
		Nielson, P E <i>et al.</i> , <i>Science</i> , 254, 1497 (1991).
		O'Neil, I. A. <i>et al.</i> , "DPPE: A Convenient Replacement for Triphenylphosphine in the Staudinger and Mitsunobu Reactions", <i>Tetrahedron Letters</i> , vol. 39, no. 42, 7787-7790 (1998). ,
		Paikoff, S F <i>et al.</i> , "The Solid Phase Synthesis of N-Alkylcarbamate Oligomers", <i>Tetrahedron Letters</i> , 37, No. 32: 5653-56 (1996).
		Rawal, V. H., Jones, R. J., Cava, M. P., <i>J. Org. Chem.</i> , 52, 19-28 (1987).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.


<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/602,521
				Filing Date	June 24, 2003
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	
Sheet	7	of	8	Attorney Docket Number	065435-9027

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		Saha K. <i>et al.</i> , <i>JOC</i> , 58, 7827 (1993).
		Schreiber <i>et al.</i> , <i>JACS</i> , 120, 23-29 (1998).
		Shimizu <i>et al.</i> , <i>J. Antibiotics</i> , 29, 2492-2503 (1982).
		Simon, R. J. <i>et al.</i> , "Peptoids: A Modular Approach to Drug Discovery", <i>Proc. Natl. Acad. Sci. USA</i> , 89, 9367-71 (1992).
		Soth, M. J. and Nowick, J. S., "Unnatural oligomer libraries", <i>Curr. Opin. Chem. Biol.</i> , 1, 120-129 (1997).
		Takeuchi <i>et al.</i> , <i>J. Antibiotics</i> , 29, 93-96 (1976)
		Thurston <i>et al.</i> , <i>Chem. Brit.</i> , 26, 767-772 (1990).
		Thurston <i>et al.</i> , <i>Chem. Rev.</i> , 1994, 433-465 (1994).
		Thurston, D. E. <i>et al.</i> , "Synthesis of a novel GC-specific covalent-binding DNA affinity-cleavage agent based on pyrrolobenzodiazepines", <i>Chemical Communications</i> , 563-565 (1996).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/602,521
				Filing Date	June 24, 2003
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	
Sheet	8	of	8	Attorney Docket Number	065435-9027

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		Thurston, D. E., <i>et al.</i> , "Effect of A-ring modifications on the DNA-binding behavior and cytotoxicity of pyrrolo[2,1-c][1,4]benzodiazepines", <i>Journal of Medicinal Chemistry</i> , vol. 42, 1951-1964 (1999).
		Thurston, D.E., "Advances in the study of Pyrrolo[2,1-c][4,1] benzodiazepine (PBD) Antitumour Antibiotics", <i>Molecular Aspects of Anticancer Drug-DNA interactions</i> , Neidle, S., Waring, M.J. eds., Macmillan Press Ltd., 1: 54-88 (1993).
		Tsunakawa, <i>et al.</i> , <i>J. Antibiotics</i> , 41, 1366-1373 (1988).
		Wilson, S. C. <i>et al.</i> , "Design and Synthesis of a Novel Epoxide-Containing Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) via a New Cyclization Procedure", <i>Tetrahedron Letters</i> , vol. 36, no. 35, 6333-6336 (1995).
		Zuckermann <i>et al.</i> , "Discovery of Nanomolecular Ligands for 7-Transmembrane G-Protein-Coupled Receptors from a Diverse N-(Substituted) glycine Peptoid Library", <i>Journal of Medicinal Chemistry</i> , 37, 2678-85 (1994).

Q:\client\065435\9027\B0251878.1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.